U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Low Grade Fallopian Tube Serous Adenocarcinoma

MedGen UID:
926338
•Concept ID:
C4288806
•
Neoplastic Process

Definition

A slow-growing serous adenocarcinoma that arises from the fallopian tube. It is characterized by the presence of low grade cytologic features and infrequent mitotic figures. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVLow Grade Fallopian Tube Serous Adenocarcinoma

Professional guidelines

PubMed

Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.
Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, Chen LM, Cristea M, DeRosa M, Eisenhauer EL, Gershenson DM, Gray HJ, Grisham R, Hakam A, Jain A, Karam A, Konecny GE, Leath CA, Liu J, Mahdi H, Martin L, Matei D, McHale M, McLean K, Miller DS, O'Malley DM, Percac-Lima S, Ratner E, Remmenga SW, Vargas R, Werner TL, Zsiros E, Burns JL, Engh AM
J Natl Compr Canc Netw 2021 Feb 2;19(2):191-226. doi: 10.6004/jnccn.2021.0007. PMID: 33545690
MEK Inhibitors for the Treatment of Low-Grade Serous Ovarian Cancer: Expanding Therapeutic Options for a Rare Ovarian Cancer Subtype.
Gershenson DM, Gourley C, Paul J
J Clin Oncol 2020 Nov 10;38(32):3731-3734. Epub 2020 Sep 8 doi: 10.1200/JCO.20.02190. PMID: 32897828
Treatment of ovarian cancer in young women.
Gershenson DM
Clin Obstet Gynecol 2012 Mar;55(1):65-74. doi: 10.1097/GRF.0b013e318248045b. PMID: 22343230

Recent clinical studies

Etiology

L1CAM is required for early dissemination of fallopian tube carcinoma precursors to the ovary.
Doberstein K, Spivak R, Reavis HD, Hooda J, Feng Y, Kroeger PT Jr, Stuckelberger S, Mills GB, Devins KM, Schwartz LE, Iwanicki MP, Fogel M, Altevogt P, Drapkin R
Commun Biol 2022 Dec 12;5(1):1362. doi: 10.1038/s42003-022-04314-8. PMID: 36509990Free PMC Article
Serous tubal intra-epithelial carcinoma: what do we really know at this point?
Vang R, Shih IM
Histopathology 2022 Nov;81(5):542-555. Epub 2022 Aug 4 doi: 10.1111/his.14722. PMID: 35859323
Genomic catastrophe, the peritoneal cavity and ovarian cancer prevention.
Yoon JY, Chapel DB, Goebel E, Qian X, Mito JK, Horowitz NS, Miron A, Soong TR, Xian W, Crum CP
J Pathol 2022 Jul;257(3):255-261. Epub 2022 Apr 18 doi: 10.1002/path.5891. PMID: 35238033
MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum.
Monk BJ, Grisham RN, Banerjee S, Kalbacher E, Mirza MR, Romero I, Vuylsteke P, Coleman RL, Hilpert F, Oza AM, Westermann A, Oehler MK, Pignata S, Aghajanian C, Colombo N, Drill E, Cibula D, Moore KN, Christy-Bittel J, Del Campo JM, Berger R, Marth C, Sehouli J, O'Malley DM, Churruca C, Boyd AP, Kristensen G, Clamp A, Ray-Coquard I, Vergote I
J Clin Oncol 2020 Nov 10;38(32):3753-3762. Epub 2020 Aug 21 doi: 10.1200/JCO.20.01164. PMID: 32822286Free PMC Article
The Dualistic Model of Ovarian Carcinogenesis: Revisited, Revised, and Expanded.
Kurman RJ, Shih IeM
Am J Pathol 2016 Apr;186(4):733-47. doi: 10.1016/j.ajpath.2015.11.011. PMID: 27012190Free PMC Article

Diagnosis

Norepinephrine induces anoikis resistance in high-grade serous ovarian cancer precursor cells.
Reavis HD, Gysler SM, McKenney GB, Knarr M, Lusk HJ, Rawat P, Rendulich HS, Mitchell MA, Berger DS, Moon JS, Ryu S, Mainigi M, Iwanicki MP, Hoon DS, Sanchez LM, Drapkin R
JCI Insight 2024 Mar 8;9(5) doi: 10.1172/jci.insight.170961. PMID: 38271085Free PMC Article
NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022.
Armstrong DK, Alvarez RD, Backes FJ, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, Chen LM, Chitiyo VC, Cristea M, DeRosa M, Eisenhauer EL, Gershenson DM, Gray HJ, Grisham R, Hakam A, Jain A, Karam A, Konecny GE, Leath CA III, Leiserowitz G, Liu J, Martin L, Matei D, McHale M, McLean K, Miller DS, Percac-Lima S, Remmenga SW, Schorge J, Stewart D, Thaker PH, Vargas R, Hendrickson AW, Werner TL, Zsiros E, Dwyer MA, Hang L
J Natl Compr Canc Netw 2022 Sep;20(9):972-980. doi: 10.6004/jnccn.2022.0047. PMID: 36075393
Serous tubal intra-epithelial carcinoma: what do we really know at this point?
Vang R, Shih IM
Histopathology 2022 Nov;81(5):542-555. Epub 2022 Aug 4 doi: 10.1111/his.14722. PMID: 35859323
Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.
Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, Chen LM, Cristea M, DeRosa M, Eisenhauer EL, Gershenson DM, Gray HJ, Grisham R, Hakam A, Jain A, Karam A, Konecny GE, Leath CA, Liu J, Mahdi H, Martin L, Matei D, McHale M, McLean K, Miller DS, O'Malley DM, Percac-Lima S, Ratner E, Remmenga SW, Vargas R, Werner TL, Zsiros E, Burns JL, Engh AM
J Natl Compr Canc Netw 2021 Feb 2;19(2):191-226. doi: 10.6004/jnccn.2021.0007. PMID: 33545690
Extrauterine Pelvic Serous Carcinomas: Current Update on Pathology and Cross-sectional Imaging Findings.
Katabathina VS, Amanullah FS, Menias CO, Chen MM, Valente PT, Chintapalli KN, Prasad SR
Radiographics 2016 May-Jun;36(3):918-32. doi: 10.1148/rg.2016150130. PMID: 27163599

Therapy

LRP1B-a prognostic marker in tubo-ovarian high-grade serous carcinoma.
Kolb S, Hoffmann I, Monjé N, Dragomir MP, Jank P, Bischoff P, Keunecke C, Pohl J, Kunze CA, Marchenko S, Schmitt WD, Kulbe H, Sers C, Sehouli J, Braicu EI, Denkert C, Darb-Esfahani S, Horst D, Sinn BV, Taube ET
Hum Pathol 2023 Nov;141:158-168. Epub 2023 Sep 22 doi: 10.1016/j.humpath.2023.09.001. PMID: 37742945
Low grade serous ovarian cancer - A rare disease with increasing therapeutic options.
Zwimpfer TA, Tal O, Geissler F, Coelho R, Rimmer N, Jacob F, Heinzelmann-Schwarz V
Cancer Treat Rev 2023 Jan;112:102497. Epub 2022 Dec 10 doi: 10.1016/j.ctrv.2022.102497. PMID: 36525716
MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum.
Monk BJ, Grisham RN, Banerjee S, Kalbacher E, Mirza MR, Romero I, Vuylsteke P, Coleman RL, Hilpert F, Oza AM, Westermann A, Oehler MK, Pignata S, Aghajanian C, Colombo N, Drill E, Cibula D, Moore KN, Christy-Bittel J, Del Campo JM, Berger R, Marth C, Sehouli J, O'Malley DM, Churruca C, Boyd AP, Kristensen G, Clamp A, Ray-Coquard I, Vergote I
J Clin Oncol 2020 Nov 10;38(32):3753-3762. Epub 2020 Aug 21 doi: 10.1200/JCO.20.01164. PMID: 32822286Free PMC Article
Ovarian High-Grade Serous Carcinoma: Assessing Pathology for Site of Origin, Staging and Post-neoadjuvant Chemotherapy Changes.
Casey L, Singh N
Surg Pathol Clin 2019 Jun;12(2):515-528. doi: 10.1016/j.path.2019.01.007. PMID: 31097113
Cancerous ovarian stem cells: obscure targets for therapy but relevant to chemoresistance.
Ahmed N, Abubaker K, Findlay J, Quinn M
J Cell Biochem 2013 Jan;114(1):21-34. doi: 10.1002/jcb.24317. PMID: 22887554

Prognosis

LRP1B-a prognostic marker in tubo-ovarian high-grade serous carcinoma.
Kolb S, Hoffmann I, Monjé N, Dragomir MP, Jank P, Bischoff P, Keunecke C, Pohl J, Kunze CA, Marchenko S, Schmitt WD, Kulbe H, Sers C, Sehouli J, Braicu EI, Denkert C, Darb-Esfahani S, Horst D, Sinn BV, Taube ET
Hum Pathol 2023 Nov;141:158-168. Epub 2023 Sep 22 doi: 10.1016/j.humpath.2023.09.001. PMID: 37742945
MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum.
Monk BJ, Grisham RN, Banerjee S, Kalbacher E, Mirza MR, Romero I, Vuylsteke P, Coleman RL, Hilpert F, Oza AM, Westermann A, Oehler MK, Pignata S, Aghajanian C, Colombo N, Drill E, Cibula D, Moore KN, Christy-Bittel J, Del Campo JM, Berger R, Marth C, Sehouli J, O'Malley DM, Churruca C, Boyd AP, Kristensen G, Clamp A, Ray-Coquard I, Vergote I
J Clin Oncol 2020 Nov 10;38(32):3753-3762. Epub 2020 Aug 21 doi: 10.1200/JCO.20.01164. PMID: 32822286Free PMC Article
Extrauterine Pelvic Serous Carcinomas: Current Update on Pathology and Cross-sectional Imaging Findings.
Katabathina VS, Amanullah FS, Menias CO, Chen MM, Valente PT, Chintapalli KN, Prasad SR
Radiographics 2016 May-Jun;36(3):918-32. doi: 10.1148/rg.2016150130. PMID: 27163599
Prophylactic salpingectomy and prophylactic salpingoophorectomy for adnexal high-grade serous epithelial carcinoma: A reappraisal.
Oliver Perez MR, Magriñá J, García AT, Jiménez Lopez JS
Surg Oncol 2015 Dec;24(4):335-44. Epub 2015 Oct 8 doi: 10.1016/j.suronc.2015.09.008. PMID: 26690823
Recent concepts of ovarian carcinogenesis: type I and type II.
Koshiyama M, Matsumura N, Konishi I
Biomed Res Int 2014;2014:934261. Epub 2014 Apr 23 doi: 10.1155/2014/934261. PMID: 24868556Free PMC Article

Clinical prediction guides

Differential epithelial and stromal LGR5 expression in ovarian carcinogenesis.
Kim H, Lee DH, Park E, Myung JK, Park JH, Kim DI, Kim SI, Lee M, Kim Y, Park CM, Hyun CL, Maeng YH, Lee C, Jang B
Sci Rep 2022 Jul 1;12(1):11200. doi: 10.1038/s41598-022-15234-2. PMID: 35778589Free PMC Article
Genomic catastrophe, the peritoneal cavity and ovarian cancer prevention.
Yoon JY, Chapel DB, Goebel E, Qian X, Mito JK, Horowitz NS, Miron A, Soong TR, Xian W, Crum CP
J Pathol 2022 Jul;257(3):255-261. Epub 2022 Apr 18 doi: 10.1002/path.5891. PMID: 35238033
MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum.
Monk BJ, Grisham RN, Banerjee S, Kalbacher E, Mirza MR, Romero I, Vuylsteke P, Coleman RL, Hilpert F, Oza AM, Westermann A, Oehler MK, Pignata S, Aghajanian C, Colombo N, Drill E, Cibula D, Moore KN, Christy-Bittel J, Del Campo JM, Berger R, Marth C, Sehouli J, O'Malley DM, Churruca C, Boyd AP, Kristensen G, Clamp A, Ray-Coquard I, Vergote I
J Clin Oncol 2020 Nov 10;38(32):3753-3762. Epub 2020 Aug 21 doi: 10.1200/JCO.20.01164. PMID: 32822286Free PMC Article
Disparities in care among patients with low-grade serous ovarian carcinoma.
Siemon J, Galli J, Slomovitz B, Schlumbrecht M
Gynecol Oncol 2020 Apr;157(1):46-54. Epub 2020 Jan 31 doi: 10.1016/j.ygyno.2019.12.041. PMID: 32008792
Ovarian High-Grade Serous Carcinoma: Assessing Pathology for Site of Origin, Staging and Post-neoadjuvant Chemotherapy Changes.
Casey L, Singh N
Surg Pathol Clin 2019 Jun;12(2):515-528. doi: 10.1016/j.path.2019.01.007. PMID: 31097113

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...